Weight Loss
-
227Thank goodness that’s over: Oilpatch has bigger things to worry about than royalty review
The recent recommendations from Alberta’s royalty review panel put me in your mind in the old joke. Here’s the abridged version: Alberta...
-
220In volatile markets, look for companies still growing their dividends: BMO
In periods of elevated market volatility, investors ought to look to stocks which are growing their dividend for stability and fortitude rather than ones...
-
251Negative interest rates in Canada could be ‘destabilizing to investor confidence’
More economists are striking the scales on negative rates of interest in Canada carrying out a Bank of Japan had become the...
-
221Lessons from the biggest ETF show on Earth
By time you’re the world’s biggest event inside the fast-growing sub-segment in the financial industry, people take notice. That was certainly the...
-
289Royalty changes hit oilfield service providers hard
Canadian oilfield services stocks swooned over fears Alberta government’s new royalty regime would erode margins for starters within the worst hit segments...
-
260World of pain: Why investors need to know how macro-economic events affect the Canadian market
This article appears in the February edition in the Financial Post Magazine. Go to the iTunes store to download the iPad edition...
-
252Bill Gross sees ‘shades of 2007’ in latest investment outlook
Bond king Bill Gross has one question for central banks: ‘How’s it workin’ for ya?’ Gross, lead portfolio manager in the Janus...
-
254All eyes on the data dump: What you need to know before markets open
North American markets look seeing a higher open today as oil prices recover slightly and investors digest a fresh batch of U.S....
-
249TSX, loonie soar as oil prices rebound; U.S. indexes mixed
TORONTO – The Toronto stock exchange rose sharply and also the Canadian dollar soared greater than a penny against its U.S. counterpart...
-
251Therapure Biopharma Inc postpones Canadian IPO because of volatile market
Therapure Biopharma Inc., a biological pharmaceuticals maker owned by Catalyst Capital Group Inc., postponed offers to sell shares in the $130 million...
